CN117531000A - New use of Ginseng radix constitution consolidating oral liquid in preventing and treating sepsis - Google Patents
New use of Ginseng radix constitution consolidating oral liquid in preventing and treating sepsis Download PDFInfo
- Publication number
- CN117531000A CN117531000A CN202210915155.2A CN202210915155A CN117531000A CN 117531000 A CN117531000 A CN 117531000A CN 202210915155 A CN202210915155 A CN 202210915155A CN 117531000 A CN117531000 A CN 117531000A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- sepsis
- ginseng
- mice
- building
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 62
- 241000208340 Araliaceae Species 0.000 title claims abstract description 61
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 61
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 61
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 61
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 47
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 20
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 5
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 35
- 108010059993 Vancomycin Proteins 0.000 abstract description 29
- 229960003165 vancomycin Drugs 0.000 abstract description 29
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract description 29
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 22
- 210000000265 leukocyte Anatomy 0.000 abstract description 11
- 210000000440 neutrophil Anatomy 0.000 abstract description 10
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 3
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 238000010172 mouse model Methods 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 5
- 241000405414 Rehmannia Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 240000006766 Cornus mas Species 0.000 description 2
- 240000002948 Ophiopogon intermedius Species 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicines, and relates to a new application of ginseng body-building oral liquid, in particular to a new application of ginseng body-building oral liquid in preventing and treating sepsis. The research result of the prevention and treatment effect of the ginseng body-building oral liquid on sepsis model mice by singly using or combining vancomycin shows that: the ginseng body-building oral liquid can improve the general state of sepsis mice, increase the body mass, reduce the death rate of sepsis mice, restore the reduced white blood cell number and the increased neutrophil percentage to be normal, and reduce the increased levels of TNF-alpha, IL-1 beta and IL-6 of sepsis patients by singly using or combining vancomycin. Compared with the conventional antibiotics, the ginseng body-building oral liquid has the advantages of difficult generation of drug resistance and no toxic or side effect, and has important clinical significance for treating sepsis.
Description
Technical Field
The invention belongs to the field of medicines, and relates to a new application of ginseng body-building oral liquid, in particular to a new application of ginseng body-building oral liquid in preventing and treating sepsis.
Background
Sepsis is a common complication following severe trauma, severe infection, burns and major surgery, manifesting as systemic inflammatory response syndrome (systemic inflammatory response syndrome, SIRS), possibly further leading to multiple organ dysfunction syndrome and circulatory failure. Sepsis has the characteristics of high incidence, rapid development, high mortality rate, high treatment cost and the like. Sepsis pathogenesis is mainly in that infection causes massive release of inflammatory mediators, further activating various cells and multiple organ systems throughout the body, ultimately leading to serious consequences.
Sepsis has been identified in 2017 as a global health-first event, with its morbidity and mortality remaining high, severely threatening human life health. With the aging of population, the increase of newborns, the increase of antibiotic resistant strains, the increase of immunodeficiency patients, the increase of infection acquired in communities and hospitals and the like, the problem of sepsis needs to be solved.
The ginseng body-building oral liquid is an exclusive product of Lunan Sanpu pharmaceutical Co Ltd, and the approval document is 'national medicine standard character Z10940013', is prepared from ginseng, rehmannia root, poria cocos, tree peony bark, prepared rehmannia root, dogwood, chinese yam, rhizoma alismatis, radix asparagi and dwarf lilyturf tuber, and has the effects of nourishing yin, tonifying qi and building up body. Can be used for treating cough due to deficiency of yin and qi, palpitation, short breath, hectic fever, soreness of waist, tinnitus, spermatorrhea, night sweat, and dry stool. In the intensive research and secondary development process of the ginseng body-building oral liquid, the inventor creatively combines the antibiotics and the ginseng body-building oral liquid for treating the sepsis, proves that the combination of the antibiotics and the ginseng body-building oral liquid has a synergistic curative effect on the sepsis, can reduce the generation of side effects, and is suitable for popularization and use in clinic. The prior art has no report on the use of the ginseng body-building oral liquid for treating the sepsis, and has no report on the use of the ginseng body-building oral liquid and antibiotics in combination for treating the sepsis.
Disclosure of Invention
In order to solve the problem of sepsis caused by infection, the invention provides a pharmaceutical composition for treating sepsis. The technical scheme of the invention is as follows:
a pharmaceutical composition for treating sepsis consists of ginseng solid-base oral liquid and antibiotics.
In the intensive research and secondary development process of the ginseng body-building oral liquid, the inventor creatively combines the antibiotics and the ginseng body-building oral liquid for treating the sepsis, proves that the combination of the antibiotics and the ginseng body-building oral liquid has a synergistic curative effect on the sepsis, can reduce the generation of side effects, and is suitable for popularization and use in clinic.
The invention also provides a combined medicine for treating sepsis, which is a combined medicine consisting of the ginseng body-building oral liquid and antibiotics which are simultaneously administered.
Further, the ginseng body-strengthening oral liquid is prepared from ginseng, rehmannia root, prepared rehmannia root, dogwood, yam, moutan bark, alisma orientale, poria cocos, radix asparagi and dwarf lilyturf tuber.
Further, the antibiotic is selected from vancomycin.
Further, the volume-mass ratio of the ginseng body-building oral liquid to the antibiotics is as follows: mass (v: m) =2: 12.5-4:12.5 (l: g).
Further, the volume-mass ratio of the ginseng body-building oral liquid to the antibiotics is as follows: mass (v: m) =4: 12.5 (l: g).
The invention also provides application of the ginseng body-building oral liquid and antibiotics serving as active ingredients in preparing medicines for treating sepsis.
In the embodiment of the invention, the ginseng body-building oral liquid and vancomycin are given to sepsis model mice, the difference of various indexes of each group of mice is observed, and the prevention and treatment effects of the ginseng body-building oral liquid and the vancomycin on sepsis are examined, so that the following findings are obtained:
the ginseng body-building oral liquid and vancomycin can play a synergistic role in improving general conditions and inflammatory symptoms of sepsis patients, not only can obviously improve general conditions of sepsis mice and increase body mass and reduce mortality of the sepsis mice, but also can better improve pathological conditions compared with the ginseng body-building oral liquid or vancomycin which is singly used, can restore the reduced white blood cell number and the increased neutrophil percentage to be normal, reduces the increased levels of TNF-alpha, IL-1 beta and IL-6 of the sepsis patients, and has a synergistic therapeutic effect on sepsis.
The ginseng body-building oral liquid and vancomycin have the following advantages when being used for treating sepsis:
1. has remarkable effect
The ginseng body-building oral liquid and vancomycin have remarkable effects of improving general conditions and inflammatory symptoms of sepsis patients, are superior to the use of vancomycin alone, are also superior to the use of ginseng body-building oral liquid alone, and have very important significance on survival prognosis of sepsis patients when combined administration.
2. Mild action and no toxic side effect
The ginseng body-building oral liquid has the advantages of mild effect, comprehensive conditioning effect on human body, less possibility of drug resistance and no toxic or side effect compared with the conventional antibiotics and hormone medicines. The combined administration can reduce the dosage and the administration period of the conventional antibiotics, thereby reducing the side effects of the antibiotics.
The foregoing description is merely an overview of the technical aspects of the present invention, and is intended to be illustrative of the embodiments of the present invention in order to make it possible to clearly understand the technical means of the present invention and to implement the present invention in accordance with the contents of the specification.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The following further illustrates the inventive content of the present invention by means of specific examples, but it should be understood that the inventive examples are not in any way limiting.
Example prevention and treatment effects of Ginseng radix Guben oral liquid and vancomycin on sepsis mice
1. Experimental method
1.1 Experimental grouping
Female Balb/c mice, total body mass (25+ -2) g, were randomly divided into normal control group, model group, vancomycin group, ginseng radix Guben oral liquid group, joint 1 group, joint 2 group, joint 3 group and joint 4 group.
1.2 modeling and packet administration
The mice of each group are fasted and water-forbidden for 12 hours before operation, after being anesthetized by adopting the ranazine and the sultai 50, the abdominal midline is cut for about 1cm, the cecum is free, the tail end ligation is carried out, and a 16-gauge needle is used for puncturing and extruding a little excrement at the 0.5cm position of the tail end of the cecum, and then the mice are sutured. Normal control mice were opened only without ligating the cecum.
Before and on the day of molding, vancomycin (12.5 mg/kg) was administered by tail intravenous injection, the ginseng-to-solid oral liquid group was administered by stomach infusion (4 ml/kg), the combined administration group was administered by stomach infusion with the same volume of physiological saline as that of the normal control group and the model group except for tail intravenous injection. The doses and modes of administration for each group were as follows:
vancomycin group: 12.5mg/kg of vancomycin is administered by intravenous injection;
ginseng radix is used for consolidating constitution: the ginseng body-building oral liquid is administrated by stomach irrigation with 4ml/kg;
combination 1 group: intravenous injection of vancomycin 12.5mg/kg and oral liquid 1ml/kg of the stomach-perfusing ginseng root-strengthening oral liquid;
in combination with group 2: intravenous injection of vancomycin 12.5mg/kg and 2ml/kg of oral liquid of the stomach-perfusing ginseng root;
combination of 3 groups: intravenous injection of vancomycin 12.5mg/kg and oral liquid of lavage ginseng for consolidating constitution 4ml/kg;
in combination with 4 groups: 12.5mg/kg of vancomycin and 6ml/kg of ginseng root-fixing oral liquid for stomach irrigation are injected intravenously.
2. Detection index
2.1 general Condition observations
The following indices were examined and recorded post-operatively: respiratory rate, mental state, behavioral activity, animal mass, and death.
2.2 Biochemical index detection
After molding for 48 hours, the mice were sampled via the orbit and placed into a tube with anticoagulant, mixed well, and the white blood cell count (white blood cell coun, WBC) and neutrophil percentage (neutrophil percentage, NE%) indicators were counted with a cytometer. After centrifugation of 1200g of the remaining blood, the upper plasma was taken and the IL-6, TNF-. Alpha.and IL-1β levels in the plasma were measured according to ELISA kit instructions.
3. Statistical treatment
All data were statistically processed using GraphPad Prism 5.0 toIndicating whether the overall data is different or not by single factor analysis of varianceIf the difference exists, the significance test is carried out by using a t test method, and the difference is statistically significant with p < 0.05.
4. Experimental results and discussion
4.1 changes in general signs, physical quality and mortality in mice
The quality of the normal control group mice is slightly reduced after molding, the quality of the 1 st d body is gradually recovered to 26.5g, the normal activity is achieved, the hair color is normal, and no death occurs; the mice in the model group showed a marked decrease in body mass in 1d after model building, showing listlessness, hair erection, shortness of breath, reduced activity, and difficulty in feeding water. There was a different reduction in mortality in each of the dosing groups compared to the model group. Compared with vancomycin and ginseng root-strengthening oral liquid for single use, mortality of mice in 1-4 groups after operation for 24 hours, 48 hours and 72 hours is obviously reduced, weight recovery trend is obvious, most activities are normal, hair color is normal, activities are reduced only individually, hair is vertical, and abnormal feeding and water intake occur. Mortality was lowest in the combination 3 groups, followed by the combination 2 groups. As the dose increased, mortality of mice in group 4 in combination increased slightly compared to group 3 in combination. The oral liquid for strengthening body resistance and the vancomycin are combined for use, so that the prognosis of sepsis can be improved, and the death rate can be reduced. The body mass change and death of each group of mice are shown in Table 1 and Table 2 respectively:
table 1 average body constitution change of mice in each group
Table 2 comparison of death status of mice in each group
4.2 expression level of inflammation index in mice of each group
The percentages of white blood cells and neutrophils for each group of mice are shown in Table 3. Compared with the normal control group, the white blood cell number of the mice in the model group is obviously reduced, the percentage of neutrophils is obviously increased, and the difference is statistically significant (p < 0.01); compared with the model group, the white blood cell number of each administration group of mice is obviously increased, the percentage of neutrophils is obviously reduced except the ginseng body-building oral liquid group, and the difference compared with the model group has statistical significance (p <0.05, p < 0.01); compared with vancomycin group and ginseng body-building oral liquid group, the combination 1-4 groups have obvious differences (p <0.05, p < 0.01) in increasing the white blood cell number of mice and reducing the percentage of neutrophils, and the combination 3 groups have optimal effect, and the combination 2 groups are the next.
The above results indicate that: the ginseng body-building oral liquid and vancomycin can obviously increase the white blood cell number of the sepsis mice, reduce the neutrophil percentage of the sepsis mice, and have synergistic prevention and treatment effects on the sepsis mice.
Table 3 percentage comparison of white blood cells and neutrophils from each group of mice
In comparison with the normal control group, # p<0.05, ## p<0.01；
in contrast to the set of models, $ p<0.05, $$ p<0.01；
in contrast to the vancomycin group, * p<0.05, ** p<0.01；
compared with the ginseng body-building oral liquid, ％ p<0.05, ％％ p<0.01。
comparison of inflammatory factor levels in mice of each group as shown in Table 4, the serum levels of TNF- α, IL-1β and IL-6 were significantly increased in the model group compared to the normal control group, and the differences were statistically significant (p < 0.05); the levels of TNF-alpha, IL-1 beta and IL-6 were significantly reduced (p <0.05, p < 0.01) in the serum of vancomycin and mice from groups 1-4 compared to the model group, were statistically significant compared to the model group, and were most significant in the 3 groups.
Table 4 comparison of inflammatory factors in mice of each group
| Group of | TNF-α(ng/ml) | IL-1β(ng/ml) | IL-6(ng/ml) |
| Normal control group | 10.01±3.5 | 29.42±5.51 | 6.65±2.82 |
| Model group | 139.69±29.68 ## | 558.02±63.2 ## | 51.73±1.88 ## |
| Vancomycin group | 78.86±13.14 $ | 407.56±56.9 $ | 40.17±5.39 $$ |
| Ginseng oral liquid group for strengthening body resistance | 95.82±6.90 $ | 464.69±78.3 | 46.11±4.25 |
| Combination of group 1 | 77.98±15.26 $$ | 441.26±37.85 $$ | 40.76±5.02 $ |
| Combination of 2 groups | 64.47±8.65 $$*％％ | 348.68±36.31 $$*％％ | 33.63±4.89 $$*％％ |
| Combination of 3 groups | 59.58±9.88 $$**％％ | 320.31±65.21 $$*％％ | 27.06±12.61 $$*％％ |
| Combination of 4 groups | 71.22±6.77 $$％％ | 371.22±62.51 $$％ | 38.06±5.67 $$％ |
In comparison with the normal control group, # p<0.05, ## p<0.01；
in contrast to the set of models, $ p<0.05, $$ p<0.01；
in combination with vancomycinThe ratio of the two components is that, * p<0.05, ** p<0.01；
compared with the ginseng body-building oral liquid, ％ p<0.05, ％％ p<0.01。
the experimental results show that: (1) The ginseng body-building oral liquid and vancomycin combined have obvious improvement effect on the recovery of the quality of the sepsis mice, and compared with the single-use ginseng body-building oral liquid and the single-use vancomycin, the ginseng body-building oral liquid and the single-use vancomycin can obviously reduce the death rate of the mice. (2) Compared with the single-use ginseng body-building oral liquid and the single-use vancomycin, the combination of the ginseng body-building oral liquid and the vancomycin can obviously reduce the serum inflammatory factor level of the sepsis mice, improve the inflammatory state of the sepsis mice, and have a synergistic effect on the sepsis when being used in combination.
Claims (10)
1. A pharmaceutical composition for treating sepsis is characterized by comprising ginseng solid oral liquid and antibiotics.
2. The use according to claim 1, wherein the volume-to-mass ratio of the ginseng solid oral liquid to the antibiotics is: mass = 2:12.5-4:12.5.
3. the use according to claim 2, wherein the volume-to-mass ratio of the ginseng solid oral liquid to the antibiotics is: mass=4: 12.5.
4. a pharmaceutical composition according to any one of claims 1 to 3, wherein the antibiotic is selected from vancomycin.
5. The combined medicine for treating sepsis is characterized in that the combined medicine is a combined medicine of ginseng body-building oral liquid and antibiotics which are simultaneously administered.
6. The combination according to claim 5, wherein the volume-to-mass ratio of the ginseng solid oral liquid to the antibiotic is: mass = 2:12.5-4:12.5.
7. the combination according to claim 6, wherein the volume-to-mass ratio of the ginseng solid oral liquid to the antibiotic is: mass=4: 12.5.
8. the combination according to any one of claims 5 to 7, wherein the antibiotic is selected from vancomycin.
9. The ginseng body-building oral liquid and antibiotics are simultaneously used as active ingredients and are used for preparing medicines for treating sepsis.
10. The use according to claim 9, wherein the volume to mass ratio of the ginseng solid oral liquid to the antibiotics is: mass = 2:12.5-4:12.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210915155.2A CN117531000A (en) | 2022-08-01 | 2022-08-01 | New use of Ginseng radix constitution consolidating oral liquid in preventing and treating sepsis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210915155.2A CN117531000A (en) | 2022-08-01 | 2022-08-01 | New use of Ginseng radix constitution consolidating oral liquid in preventing and treating sepsis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117531000A true CN117531000A (en) | 2024-02-09 |
Family
ID=89784755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210915155.2A Pending CN117531000A (en) | 2022-08-01 | 2022-08-01 | New use of Ginseng radix constitution consolidating oral liquid in preventing and treating sepsis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117531000A (en) |
-
2022
- 2022-08-01 CN CN202210915155.2A patent/CN117531000A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117137998B (en) | Pharmaceutical composition for treating yin deficiency damp-heat type viral infection and pulmonary nodule, preparation and application thereof | |
| CN101049345B (en) | A preparation for treating disease of oral cavity and gorge, and preparation method | |
| CN101732413B (en) | Chinese medicinal composition for treating arthromyodynia and preparation method thereof | |
| CN117531000A (en) | New use of Ginseng radix constitution consolidating oral liquid in preventing and treating sepsis | |
| CN102397458B (en) | Medicinal composition for treating senile pneumonia and preparation method thereof | |
| CN101167734A (en) | Composition for bi-directional regulation of smooth muscle contraction in the gastrointestinal tract | |
| CN114515307A (en) | A veterinary drug composition or animal food additive for preventing and/or treating kidney diseases | |
| CN1660218A (en) | A kind of traditional Chinese medicine preparation for treating male diseases | |
| CN106619765B (en) | A pharmaceutical composition containing caulis Marsdeniae Tenacissimae extract | |
| CN105497469B (en) | Traditional Chinese medicine compound composition with anti-pulmonary fibrosis effect and its preparation method and application | |
| CN100525783C (en) | Application of Rangoon creeper fruit and its extracts in preparation of medicine for promoting lead expelling | |
| CN111000983A (en) | Medicinal use of new recombinant human interleukin-1 receptor antagonist | |
| CN118542906B (en) | A Chinese medicine composition for improving pulmonary fibrosis and pulmonary nodules and its preparation method | |
| CN113440557B (en) | Traditional Chinese medicine composition for treating constipation and preparation method thereof | |
| CN113876864B (en) | Pharmaceutical composition for treating infertility and preparation method and application thereof | |
| CN107349303B (en) | A kind of traditional Chinese medicine composition for treating chronic chest pain and application thereof | |
| CN103830584A (en) | Medicament for treating vertebral artery ischemic disease and preparation method thereof | |
| CN100443093C (en) | drugs to treat AIDS | |
| CN109091667B (en) | Application of human urinary kallidinogenase in preparing medicine for treating migraine and composition thereof | |
| CN107184651B (en) | Traditional Chinese medicine composition for clearing away heat and toxic materials and preparation method and application thereof | |
| CN1481892A (en) | Reptile phrynosoma tablet for curing pulmonary disease | |
| CN113730468A (en) | Traditional Chinese medicine composition for treating sepsis and preparation method and application thereof | |
| CN104474227A (en) | Traditional Chinese medicine composition for treating hepatitis complicated with aplastic anemia | |
| CN114224937A (en) | Use of Qiyinsanliangsan for the treatment of diarrhea | |
| CN117752670A (en) | Traditional Chinese medicine composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |